MediPharm Labs Executing on International Cannabis Extracts Strategy


Robin Lefferts

April 25th, 2019

Exclusive, News, Top Story


Canadian companies have a bit of a head start on those from other countries where the legal cannabis framework is not as comprehensive or advanced. In many ways, countries around the globe look to Canada as a model. In fact, Australia has basically adopted Canadian medical regulations and is a few years behind Canada in terms of the development of the industry. With Europe and South America quickly developing, Thailand and New Zealand recently approving medical marijuana, and the Philippines looking like it might, the global cannabis market is coming into focus.

MediPharm Labs (TSXV: LABS) (OTCQB: MEDIF) (FSE:MLZ) is a Canadian company that sees the opportunity clearly and is executing on a comprehensive global strategy. Positioned as a cannabis extracts expert in Canada, the company is building out Australian operations while recently inking its first sale of cannabis oil to an Australian company. Its Canadian production facility is pursuing European Union GMP certification, which are the world’s highest standards. Once certified, the company will have export access to not only the European countries but to many other jurisdictions that rely on EU GMP certification to ensure quality.

Please click here to see MediPharm’s corporate presentation and stay up to date with developments.

Australia the First International Step

MediPharm Labs is a company of firsts. It was the first Canadian Licensed Producer to focus solely on extracts, bypassing the customary first step of attaining a cultivation license and moving straight to the oils and extracts. It won first place as the Cannabis Start-Up of the Year at the 2018 Canadian Cannabis Awards. MediPharm Labs’ deal to ship oils to Australia makes it the first Canadian extracts-only producer to export products there.

The two-year deal has MediPharm Labs selling cannabis resin to AusCann, an Australian medical marijuana company. AusCann will utilize the resin as the basis for its cannabinoid pharmaceutical product development, associated clinical trials, and for its introduction of hard-shell cannabinoid capsules to the country’s medical marijuana patients. AusCann also has a supply agreement with Canopy Growth, which has its own extraction capabilities. Importantly, Canopy Growth also has a major oil sales agreement whereby it has committed to purchase up to 900kg of cannabis concentrate from MediPharm Labs. Both companies recognize the value MediPharm Labs brings to the extract market.

AusCann CEO Dr. Paul MacLeman stated, “MediPharm Labs’ significant market share combined with proprietary methodology ensures reliable supply of pharma-grade cannabinoid extracts and AusCann’s continued ability to develop and deliver quality cannabinoid medicines for distribution in Australia. Critical to our process is repeatability in manufacturing, reliable dosing, and purity assurance. MediPharm Labs’ concentrates will form an important foundation to our products that will allow delivery of effective, trusted and safe medicines for the treatment of chronic pain.”

The Australian medical market is just getting off the ground. The government agency overseeing the medical cannabis applications, the Therapeutic Goods Administration (TGA), reports that it has approved over 3000 personal medical marijuana applications in the last year or so. The pace has picked up substantially, with the 37 approved applications from last February steadily increasing to 672 in January of this year. The TGA instituted an online system to accommodate the increasing demand in July 2018.

In 2010, a survey of Australians regarding cannabis use showed that around 750,000 people used the drug weekly, while about 300,000 smoked every day. So there is definitely a black market in the country ready for further legalization.

Please click here to see MediPharm Lab’s corporate presentation and stay up to date with developments.

The Bigger Picture

MediPharm Labs is laying the groundwork in the emerging Australian market, not only with its export program but with construction of a production facility modeled after its Canadian operations. The company anticipates serving both the Australian domestic market and the broader Asia-Pacific export market from the new facility. That export opportunity is quickly expanding.

Artist impression of a MediPharm Labs production facility in Australia

New Zealand recently broadened its medical program, with the new government allowing more chronic pain sufferers and terminally ill patients access to the drug. The government also pledged to put full legalization on the ballot in 2020. In December 2018, Thailand became the first country in Southeast Asia to legalize medical marijuana. The Malaysian health ministry opened up the possibility of allowing medical use, saying it would consider legalization for certain health conditions if the treatment could be proven safe and effective. Even Philippines President Rodrigo Duterte, known for running ruthless and bloody anti-drug campaigns, has stated he would sign a medical marijuana bill currently under consideration in the country’s legislature.

By transferring its institutional expertise from Canadian operations into its fledgling Australian operations, MediPharm is positioning to capitalize on the cannabis awakening across the region. Its extracts form the basis for a myriad of cannabis products, both recreational and medicinal. Medical patients often shy away from smoking flower for the obvious health concerns, and recreational users in maturing markets demonstrate the same tendency. With capsules, oils, edibles, tinctures, creams, and other delivery mechanisms becoming ever more popular and practical, MediPharm Labs’ focus on the underlying active ingredients could prove prescient.

The company bears watching over the coming quarters with several potential catalysts on the horizon. The completion of construction and licensing in Australia, the expansion of capacity in Canada, the EU GMP certification of those facilities, the signing of more concentrate deals both domestically and internationally, the penetration of new international markets … all of these events appear likely in the near future, and bode very well for the implementation of MediPharm Labs’ comprehensive global strategy.

Please click here to see MediPharm’s corporate presentation and stay up to date with developments.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Avatar

About Robin Lefferts



Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading